Thermo Fisher Scientific Inc. (NYSE:TMO) is James Hambro & Partners’ 7th Largest Position

James Hambro & Partners boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 131,249 shares of the medical research company’s stock after purchasing an additional 11,906 shares during the period. Thermo Fisher Scientific makes up 5.5% of James Hambro & Partners’ portfolio, making the stock its 7th largest position. James Hambro & Partners’ holdings in Thermo Fisher Scientific were worth $59,948,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of TMO. Eudaimonia Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 248.1% during the third quarter. Eudaimonia Partners LLC now owns 536 shares of the medical research company’s stock valued at $237,000 after purchasing an additional 382 shares during the last quarter. Red Spruce Capital LLC grew its stake in shares of Thermo Fisher Scientific by 8.6% during the fourth quarter. Red Spruce Capital LLC now owns 993 shares of the medical research company’s stock valued at $463,000 after buying an additional 79 shares during the last quarter. Private Trust Co. NA boosted its stake in shares of Thermo Fisher Scientific by 1.7% during the fourth quarter. Private Trust Co. NA now owns 7,639 shares of the medical research company’s stock valued at $3,558,000 after purchasing an additional 129 shares during the period. Woodstock Corp grew its position in shares of Thermo Fisher Scientific by 7.8% during the 4th quarter. Woodstock Corp now owns 17,024 shares of the medical research company’s stock worth $7,929,000 after buying an additional 1,233 shares in the last quarter. Finally, Fulton Bank N.A. increased its holdings in shares of Thermo Fisher Scientific by 3.7% in the 4th quarter. Fulton Bank N.A. now owns 4,543 shares of the medical research company’s stock valued at $2,116,000 after acquiring an additional 162 shares during the period. Institutional investors own 87.17% of the company’s stock.

Several brokerages have commented on TMO. Credit Suisse Group lifted their price objective on shares of Thermo Fisher Scientific from $556.00 to $580.00 in a research note on Tuesday, January 12th. UBS Group dropped their target price on shares of Thermo Fisher Scientific from $588.00 to $560.00 and set a “buy” rating for the company in a report on Monday, March 29th. KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $520.00 target price on the stock in a report on Wednesday, March 24th. SVB Leerink raised their price objective on shares of Thermo Fisher Scientific from $525.00 to $560.00 and gave the stock an “outperform” rating in a report on Tuesday, February 2nd. Finally, Citigroup increased their price objective on Thermo Fisher Scientific from $500.00 to $530.00 and gave the stock a “buy” rating in a research report on Tuesday, February 2nd. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $534.45.

Shares of TMO stock opened at $467.38 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.93 and a quick ratio of 2.31. The stock has a market capitalization of $183.69 billion, a PE ratio of 38.31, a P/E/G ratio of 1.40 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1-year low of $324.35 and a 1-year high of $532.57. The business has a 50-day moving average of $468.08 and a 200 day moving average of $476.02.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, April 29th. The medical research company reported $7.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.69 by $0.52. The business had revenue of $9.91 billion during the quarter, compared to analysts’ expectations of $9.69 billion. Thermo Fisher Scientific had a net margin of 17.12% and a return on equity of 21.35%. The business’s revenue for the quarter was up 59.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.94 earnings per share. Analysts anticipate that Thermo Fisher Scientific Inc. will post 19.03 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, April 16th. Investors of record on Tuesday, March 16th were paid a $0.26 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend was Monday, March 15th. This represents a $1.04 annualized dividend and a yield of 0.22%. Thermo Fisher Scientific’s payout ratio is currently 8.42%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also: Why do companies engage in swaps?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.